LFCR

Lifecore Biomedical Inc. (LFCR) | Rumor.io

Lifecore Biomedical

LFCR

Attention (50-day avg)0%

Attention rank (50-day avg)#3,356

Bullish sentiment (50-day avg)92%

Price to earnings ratio56.2

Market capitalization246.8M

Earnings per share-1.27

Dividend yield (TTM)—

Revenue (annual)128.9M

Net income (annual)-38.7M

Social

What share of all stock conversation is about LFCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% new	0% +0	0% 0

Sep 28

Lifecore Biomedical, Inc. ($LFCR) will be acquired by Webster Equity Partners for $6.28 cash per share plus CVRs, with a total value potentially reaching $664 million if targets are met.
$LFCR stock added calls and shares today after the acquisition news, and is expected to bounce back this week.
The acquisition deal will result in a cash payout of $6.28 per share, with the possibility of additional value from CVRs and the "go shop" period.

Generated by AI

Sentiment

Of the messages about LFCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +33.33	73.33% -12.41
Bearish	—	0%	0% -33.33	26.67% +12.41

May 23

Lifecore Biomedical, Inc. secured a new $150M financing agreement with its long-term customer, driving the stock up by 45%.
The company's debt refinancing announcement has been a significant catalyst for the stock's 55% increase.
Lifecore Biomedical, Inc. has shown strong intraday and daily performance, with a 56% increase in a single day and a 38.4% rise after a gap down.

Generated by AI

Topics

Of the messages about LFCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	59.89%
Controversies	—	0%	0%	3.95%
Analysts	—	0%	0%	0%
Earnings	—	0%	0%	34.46%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	1.69%

May 23

Lifecore Biomedical, Inc. (LFCR) has entered into a new $150.0 million financing agreement with Alcon, replacing its existing term loan with more favorable terms.
The company has also signed a new supply agreement with Alcon to expand its HA fermentation capacity, further solidifying its long-term partnership.
As a result of the new financing and supply agreement, LFCR's stock price surged 22.6% in pre-market trading.

Generated by AI

Community

Of the messages about LFCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	75.61%	67.35%	55.81%
Newcomers	—	24.39%	32.65%	44.19%

Mar 16

The newcomers are focused on Lifecore Biomedical's (LFCR) disappointing earnings and outlook, with one user suggesting that paying 14 EBITDA for a CDMO at 20% capacity with reasonable probability of a buyout in the next 3 years doesn't look that bad.
Another concern is the company's lack of revenue growth, with one user pointing out that they are losing $30M/yr at 20% capacity and it's hard to believe they couldn't increase the percentage this year.
The newcomers are also discussing Lifecore Biomedical's missed sales estimates, with one user stating that the company's stock declined following its Q2 financial report, which showed mixed results, and its FY26 sales forecast, which fell short of expectations.

Generated by AI

News

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)

17h agoMorningstar

Lifecore Biomedical: Bid Is Underwhelming (NASDAQ:LFCR)

Lifecore Biomedical agreed to be acquired for $6.28/share in cash plus up to $3.39/share in CVRs. See why I rate LFCR stock a Hold right now.

21h agoSeeking Alpha

LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.

1d agoMorningstar

Webster Equity Partners to acquire Lifecore for up to $663.7m

1d agoInvesting.com

Lifecore Biomedical to be Acquired by Webster Equity Partners

Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% PremiumLifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at ClosingBoth Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance MilestonesStockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CV

1d agoYahoo Finance

Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business (NASDAQ:LFCR)

15d agoSeeking Alpha

Also Discussed

Investors talking about LFCR also mention

#	Name	Attention
1	First Guaranty Bancshares 6.75% Perpetual Preferred StockFGBIP	0%0
2	Aemetis Inc.AMTX	0%-0.01
3	Thryv Holdings Inc.THRY	0%0
4	Cellebrite DI Ltd.CLBT	0%0
5	TTSH - Tile Shop Holdings, Inc.	——
6	CDMO - Avid Bioservices, Inc.	——
7	MEIP - MEI Pharma, Inc.	——
8	Avanos Medical Inc.AVNS	0%0
9	SoundHound AI, Inc.SOUNW	0%new
10	Jiayin Group Inc. ADRJFIN	0%new

Lifecore Biomedical Inc.

Healthcare
Drug Manufacturers - Specialty & Generic

Lifecore Biomedical Inc. is a contract development and manufacturing organization focused on sterile injectable pharmaceuticals and medical device products. The company provides development, aseptic fill-finish, and commercial manufacturing services for products packaged in syringes, vials, and cartridges. It also produces pharmaceutical-grade hyaluronic acid, a biomaterial used in a range of medical applications, including ophthalmic and orthopedic products. Lifecore Biomedical Inc. serves pharmaceutical and medical device customers that need regulated manufacturing expertise, formulation support, and process scale-up capabilities. Headquartered in Chaska, Minnesota, the company operates in the biopharmaceutical manufacturing and biomaterials markets, where it plays a specialized role in supporting complex injectable therapies and related healthcare products.

Website

Location

3515 Lyman Boulevard

Chaska, MN, 55318

United States

Social

What share of all stock conversation is about LFCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% new	0% +0	0% 0

Sep 28

Lifecore Biomedical, Inc. ($LFCR) will be acquired by Webster Equity Partners for $6.28 cash per share plus CVRs, with a total value potentially reaching $664 million if targets are met.
$LFCR stock added calls and shares today after the acquisition news, and is expected to bounce back this week.
The acquisition deal will result in a cash payout of $6.28 per share, with the possibility of additional value from CVRs and the "go shop" period.

Generated by AI

Sentiment

Of the messages about LFCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% +33.33	73.33% -12.41
Bearish	—	0%	0% -33.33	26.67% +12.41

May 23

Lifecore Biomedical, Inc. secured a new $150M financing agreement with its long-term customer, driving the stock up by 45%.
The company's debt refinancing announcement has been a significant catalyst for the stock's 55% increase.
Lifecore Biomedical, Inc. has shown strong intraday and daily performance, with a 56% increase in a single day and a 38.4% rise after a gap down.

Generated by AI

Topics

Of the messages about LFCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	59.89%
Controversies	—	0%	0%	3.95%
Analysts	—	0%	0%	0%
Earnings	—	0%	0%	34.46%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	1.69%

May 23

Lifecore Biomedical, Inc. (LFCR) has entered into a new $150.0 million financing agreement with Alcon, replacing its existing term loan with more favorable terms.
The company has also signed a new supply agreement with Alcon to expand its HA fermentation capacity, further solidifying its long-term partnership.
As a result of the new financing and supply agreement, LFCR's stock price surged 22.6% in pre-market trading.

Generated by AI

Community

Of the messages about LFCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	75.61%	67.35%	55.81%
Newcomers	—	24.39%	32.65%	44.19%

Mar 16

The newcomers are focused on Lifecore Biomedical's (LFCR) disappointing earnings and outlook, with one user suggesting that paying 14 EBITDA for a CDMO at 20% capacity with reasonable probability of a buyout in the next 3 years doesn't look that bad.
Another concern is the company's lack of revenue growth, with one user pointing out that they are losing $30M/yr at 20% capacity and it's hard to believe they couldn't increase the percentage this year.
The newcomers are also discussing Lifecore Biomedical's missed sales estimates, with one user stating that the company's stock declined following its Q2 financial report, which showed mixed results, and its FY26 sales forecast, which fell short of expectations.

Generated by AI

Lifecore Biomedical

Social

Sep 28

May 23

May 23

Mar 16

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)

Lifecore Biomedical: Bid Is Underwhelming (NASDAQ:LFCR)

LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.

Webster Equity Partners to acquire Lifecore for up to $663.7m

Lifecore Biomedical to be Acquired by Webster Equity Partners

Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business (NASDAQ:LFCR)

Also Discussed

Lifecore Biomedical Inc.

Company Information

Location

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)

Lifecore Biomedical: Bid Is Underwhelming (NASDAQ:LFCR)

LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.

Webster Equity Partners to acquire Lifecore for up to $663.7m

Lifecore Biomedical to be Acquired by Webster Equity Partners

Lifecore Biomedical: A Messy Balance Sheet, A Much Better Business (NASDAQ:LFCR)

Also Discussed

Social

Sep 28

May 23

May 23

Mar 16